Hylase „dessau“

Hyaluronidase, the active ingredient in Hylase Dessau, is a hydrolase (enzyme) presented as an injectable solution for intramuscular use. It hydrolyzes hyaluronic acid to increase tissue permeability, facilitating the dispersion and absorption of co‑administered drugs and aiding in the treatment of chemotherapy extravasation. GNH USA supplies Hylase Dessau as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide.

Hylase Dessau acts on the extracellular matrix to modify tissue permeability, enabling several clinical applications. - Enhancement of absorption of subcutaneously or intramuscularly administered drugs: Increases tissue permeability to improve uptake of co‑administered agents. - Facilitation of subcutaneous fluid administration: Allows larger volumes of fluid to be given subcutaneously with reduced discomfort. - Treatment of extravasation of vesicant chemotherapy agents: Promotes dispersion of infiltrated chemotherapeutic agents, reducing local tissue injury.

Adverse reactions may occur following intramuscular administration of hyaluronidase.

Common Side Effects: - Local pain or tenderness at the injection site. - Redness or mild swelling around the injection area. - Transient itching or rash. - Low‑grade fever. - Headache.

Serious or Rare Side Effects: - Immediate hypersensitivity reactions, including anaphylaxis. - Severe edema or tissue necrosis at the injection site. - Systemic allergic manifestations such as urticaria or bronchospasm. - Rare cardiovascular events like hypotension.

When using Hylase Dessau, consider the following safety measures. - Allergy assessment: Verify no known hypersensitivity to hyaluronidase or related enzymes. - Injection technique: Use proper intramuscular technique to minimize tissue trauma. - Monitoring: Observe patients for signs of allergic reaction during and after administration. - Drug interactions: Review concomitant medications that may increase bleeding risk. - Contraindications: Avoid in patients with a history of severe anaphylaxis to enzyme products. - Store at 2-8°C: Keep refrigerated, protect from light, do not freeze or shake.

Hylase Dessau may interact with other agents; awareness of the interaction level guides clinical decisions.

Major Interactions (Avoid): - Co‑administration with other hyaluronidase‑containing products: risk of cumulative enzymatic activity. - Concurrent high‑dose anticoagulants: may exacerbate bleeding at the injection site. - Use with intravascular vesicant chemotherapy agents: could worsen tissue injury if extravasation occurs.

Moderate Interactions (Monitor Closely): - Combination with other tissue‑degrading enzymes (e.g., collagenase): monitor for excessive tissue breakdown. - Concurrent immunosuppressants: observe for altered immune response. - Large‑volume subcutaneous fluids given with hyaluronidase: monitor for local edema.